XERS Award Disclosure
Taddese Menassie · SEC Form 4 · Filed Nov 4, 2026
Award
Calculated transaction value
$320.34K
Taddese Menassie Director
XERS
Transaction date
Nov 2, 2026
Public filing date
Nov 4, 2026
Filing lag
Filed 2 days later
XERS daily price context
Close on/before transaction
$10.17
Nov 2, 2026
First close after public filing
--
Unavailable
30-day return after filing
--
Through Unavailable
Source details
- Reported owner
- Not disclosed
- Source asset code
- Derivative
- Security
- Stock Option (Right to Buy) on Common Stock
- Quantity / price
- 31,499 shares @ $10.17
- SEC ownership
- Direct
- Transaction code
- A
- Form
- 4
- Filing identifier
- 0001867096-26-000105
Filing cohort
Transactions in this filing
Showing 2 of 2
Trades
2
Issuers
1
Estimated value
$320.34K
Buys / sales
0 / 0
| Issuer | Transaction | Traded | Value |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. XERS | Award | Nov 2, 2026 | $0 |
| Xeris Biopharma Holdings, Inc. XERS Current | Award | Nov 2, 2026 | $320.34K |